J Cancer 2020; 11(1):100-107. doi:10.7150/jca.36380 This issue
1. Department of Musculoskeletal Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
Liposarcoma is a malignant tumor of mesenchymal origin with significant tissue diversity. It is composed of adipocytes with different degrees of differentiation and different degrees of heteromorphosis. It is not sensitive to traditional radiotherapy and chemotherapy and has a poor prognosis. In recent years, with the rapid development of basic immunology, molecular genetics and tumor molecular biology, the histological classification of liposarcoma has become increasingly clear. More and more new methods and technologies, such as gene expression profile analysis, the whole genome sequencing, miRNA expression profile analysis and RNA sequencing, have been successfully applied to liposarcoma, bringing about a deeper understanding of gene expression changes and molecular pathogenic mechanisms in the occurrence and development of liposarcoma. This study reviews the present research status and progress of cellular and molecular alterations of liposarcoma and corresponding clinical treatment progress.
Keywords: Liposarcoma, Cytogenetics, Molecular genetics, Epigenetics, Clinical Treatment